Team Portfolio Raise Essays

F4/Mass General Brigham Ventures/Activity

Mass General Brigham Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

5 investments· MAY 2026 – NOV 2026Show all

Investment

Participated in Oyster Therapeutics' $60M Series A led by 4BIO Capital.

Oyster Therapeutics

Oyster Therapeutics Mass General Brigham Ventures

theventurecodex.comNOV 2026

NOV 2026

Investment

Participated in Abcuro's $66M Series D led by New Leaf Venture Partners.

Abcuro

Abcuro Mass General Brigham Ventures

theventurecodex.comAUG 2026

AUG 2026

Investment

Participated in Claris Biotherapeutics' $118M Series B.

Claris Bio

Claris Bio Mass General Brigham Ventures

theventurecodex.comJUL 2026

JUL 2026

Investment

Participated in InStride Health's $30M Series C.

InStride Health

InStride Health Mass General Brigham Ventures

theventurecodex.comJUN 2026

JUN 2026

Investment

Participated in Violet Therapeutics' $5M seed led by LifeSpan Vision Ventures.

Violet Therapeutics

Violet Therapeutics Mass General Brigham Ventures

theventurecodex.comMAY 2026

MAY 2026

Exit

Portfolio company Verve Therapeutics acquired by Eli Lilly.

Verve Therapeutics

Verve Therapeutics Mass General Brigham Ventures

research.massgeneralbrigham.orgAUG 2025

AUG 2025

Exit

Portfolio company Scorpion acquired by Eli Lilly.

Scorpion

Scorpion Mass General Brigham Ventures

research.massgeneralbrigham.orgJAN 2025

JAN 2025

Mass General Brigham Ventures | Activity | F4